EUVIMEDEUVIMED entdecken
Crossref

Investigation of the efficacy and adverse effects of lacosamide over 36 months

Kei Wakabayashi, Hitoshi Osaka, Hirokazu Yamagishi, Mari Kuwajima, Takahiro Ikeda, Ayumi Matsumoto, Kazuhiro Muramatsu, Takanori Yamagata

Epilepsy & Behavior · 2023

DOI: 10.1016/j.yebeh.2023.109227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2023. Verfasst von Kei Wakabayashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Jichi Medical University, Division of Human Genetics, Center for Molecular Medicine, Jichi Medical University, Japan. Elect…. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Generalized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy and retention rate of lacosamide (LCM) over 36 months as a treatment for children and adolescents with focal and generalized epilepsy based on a retrospective study. METHODS: All patients prescribed LCM as monotherapy and add-on therapy between October 2016 and September 2019 at Jichi Children's Medical Center Tochigi were included in the study. The response rate, retention rate, and adverse effects were calculated. RESULTS: A total of 126 (female, n = 73) patients of 1.3 to 34.9 years old (median age: 12.8 years; mean ± SD 13.2 ± 6.6 years) received LCM as monotherapy or add-on treatment for focal, generalized, and combined focal and generalized epilepsy. The response rate was 40.5% at 3 months, 40.5% at 6 months, 38.1% at 9 months, 35.7% at 12 months, 25.9% at 24 months, and 29.4% at 36 months. For 34 patients who were observable for 36 months, the retention rate was 70.6% at 3 months, but then gradually declined to 34.8% at 36 months. According to the number of concomitant anti-seizure medications (ASMs), the retention rate was higher in patients receiving

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsy, GeneralizedChildAdolescentHumansFemaleInfantChild, PreschoolYoung AdultAdultLacosamideRetrospective StudiesProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

Antiepileptic drugChildrenLacosamideResponse rateRetention rate

Substanzen

LacosamideAnticonvulsants

Autor:innen und Institutionen

  • Department of Pediatrics, Jichi Medical University, Division of Human Genetics, Center for Molecular Medicine, Jichi Medical University, Japan. Electronic address: r1245wk@jichi.ac.jp.
  • Department of Pediatrics, Jichi Medical University, Division of Human Genetics, Center for Molecular Medicine, Jichi Medical University, Japan. Electronic address: hosaka@jichi.ac.jp.
  • Department of Pediatrics, Jichi Medical University, Division of Human Genetics, Center for Molecular Medicine, Jichi Medical University, Japan.

Zitieren

APA

Wakabayashi, K., Osaka, H., Yamagishi, H., Kuwajima, M., Ikeda, T., Matsumoto, A., Muramatsu, K., & Yamagata, T. (2023). Investigation of the efficacy and adverse effects of lacosamide over 36 months. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2023.109227

Vancouver

Wakabayashi K, Osaka H, Yamagishi H, Kuwajima M, Ikeda T, Matsumoto A, et al. Investigation of the efficacy and adverse effects of lacosamide over 36 months. Epilepsy & Behavior. 2023. doi:10.1016/j.yebeh.2023.109227

BibTeX
@article{Wakabayashi2023,
  author = {Wakabayashi, Kei and Osaka, Hitoshi and Yamagishi, Hirokazu and Kuwajima, Mari and Ikeda, Takahiro and Matsumoto, Ayumi and Muramatsu, Kazuhiro and Yamagata, Takanori},
  title = {Investigation of the efficacy and adverse effects of lacosamide over 36 months},
  journal = {Epilepsy & Behavior},
  year = {2023},
  doi = {10.1016/j.yebeh.2023.109227}
}
Kostenlos starten →